|
|
50 Lakeview Parkway, Suite 111
Vernon Hills, IL 60061 USA
phone:847-573-8000
fax:847-573-8030
|
|
| Symbol |
APSN |
| Exchange |
OTC |
| Founded |
1992 |
| Employees |
6 |
|
|
| www.appliedneurosolutions.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Products for the early diagnosis and treatment of Alzheimer's disease |
|
| Management |
Craig S. Taylor, Ph.D., President and CEO, has been President, Chief Executive Officer and a Director since September 2009.
Peter Davies, Ph.D., has been involved with the Company since 1992 as the founding scientist of the Company's core Alzheimer?s technology.
David Ellison, CPA, CFO, has been Chief Financial Officer of the Company since May 1996 and Corporate Secretary since August 1999. |
| |
|
|
|
|
|
|
|
| Keywords |
| alzheimer, Tau, serum based diagnostic tests |
|
|
|
| Description |
|
Applied NeuroSolutions, Inc. (OTC.BB:APSN) is a development stage biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease (AD). |
|
| Products / Services |
Diagnostic Programs
Applied NeuroSolutions is developing serum-based tests to detect Alzheimer's disease at a very early stage in the disease process. The diagnostic platform is based on the scientific finding that the protein tau is directly linked to the pathology of Alzheimer?s disease. Upon completion of development, the blood-based test will be commercialized in 2011.
Therapeutic Program - Collaboration with Eli Lilly and Company
Applied NeuroSolutions and Lilly are engaged in the discovery and development of novel therapeutics for the treatment of Alzheimer?s disease.
|
|
| Technology / Differentiation |
| Applied NeuroSolution's core technology in the Alzheimer's disease field is based on exclusive licenses with Albert Einstein College of Medicine (?AECOM?) covering all diagnostic and therapeutic applications in the field of neurodegenerative disease discovered in the AECOM laboratories of Peter Davies, Ph.D. Dr. Davies, the Company?s founding scientist, is the Burton P. and Judith Resnick Professor of Alzheimer?s Disease Research at AECOM, and was the recipient of the Lifetime Achievement Award in Alzheimer?s Disease in July 2008. |
|
| Market / Customers |
Alzheimer?s disease is the most common cause of dementia among people age 65 and older. Dementia is the loss of memory, reason, judgment and language to such an extent that it interferes with a person?s daily life and activities. Currently it is estimated that over five million people in the U.S., and almost 35 million worldwide, have Alzheimer?s disease and the national cost of caring for people with Alzheimer?s is estimated to exceed $148 billion annually.
|
|
| Status |
| We are raising $2-5 million. The milestone payments from our Lilly collaboration and diagnostic partnerships could contribute significant cash over the next several years, and our serum diagnostic will be commercial in 18 months. We project the business will be cash flow break even in 3 years. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members